Clinical Trial Update: Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating DS-8201a (trastuzumab deruxtecan) effect on QT/QTc interval and pharmacokinetics in HER2-expressing breast cancer has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Malignant Neoplasm of Breast

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Malignant Neoplasm of Breast | Phase 1 | Status: COMPLETED | Results posted: 2021-06-14